Low-dose acetylsalicylic acid and gastrointestinal ulcers or bleeding - a cohort study of the effects of proton pump inhibitor use patterns

Journal of Internal Medicine

Volumn 274, Issue 4, 2013, Pages 371-380

  Hedberg, J ^a   Sundstrom J ^a   Thuresson, M ^b   Aarskog, P ^c   Oldgren, J ^a   Bodegard, J ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b STATISTICON AB   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Acetylsalicylic acid; Medication adherence; Peptic ulcer; Prophylaxis; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROTON PUMP INHIBITOR; STEROID;

AGED; ARTICLE; COHORT ANALYSIS; DIGESTIVE SYSTEM ULCER; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ACETYLSALICYLIC ACID; MEDICATION ADHERENCE; PEPTIC ULCER; PROPHYLAXIS; PROTON PUMP INHIBITORS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; SWEDEN;

EID: 84883739771     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12103     Document Type: Article

References (30)

1. Antithrombotic Trialists C, Baigent C, Blackwell L et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. Force USPST. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.
3. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
4. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16: 1945-53.
5. Yeomans ND, Lanas AI, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801.
6. Laheij RJ, Van Rossum LG, Jansen JB, Verheugt FW. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther 2003; 18: 109-15.
7. Taha AS, Angerson WJ, Prasad R, McCloskey C, Gilmour D, Morran CG. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 28: 878-85.
8. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
9. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23: 163-73.
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
11. Moberg C, Naesdal J, Svedberg LE, Duchateau D, Harte N. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk. Patient 2011; 4: 103-13.
12. Pratt S, Thompson VJ, Elkin EP, Naesdal J, Sorstadius E. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 2010; 10: 281-8.
13. Collet JP, Montalescot G, Blanchet B et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110: 2361-7.
14. De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005; 252: 1316-21.
15. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
16. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010; 10: 125-41.
17. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-74.
18. Derogar M, Sandblom G, Lundell L et al. Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol 2013; 11: 38-42.
19. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-909.
20. Yeomans N, Lanas A, Labenz J et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103: 2465-73.
21. Sugano K, Matsumoto Y, Itabashi T et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2011; 46: 724-35.
22. Scheiman JM, Devereaux PJ, Herlitz J et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart 2011; 97: 797-802.
23. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450.
24. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-10.
25. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. BMC Med Res Methodol 2008; 8: 70.
26. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: Foundation for Statistical Computing, 2008.
27. Furler J, Magin P, Pirotta M, van Driel M. Participant demographics reported in "Table 1" of randomised controlled trials: a case of "inverse evidence"? Int J Equity Health 2012; 11: 14.
28. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 2003; 89: 327-8.
29. Charlot M, Grove EL, Hansen PR et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690.
30. Niv Y, Battler A, Abuksis G, Gal E, Sapoznikov B, Vilkin A. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005; 50: 78-80.